Movement Alert｜Neurocrine Biosciences Falls 9.92% in Regular Trading, Stock Under Pressure Despite Massive Q2 Earnings Beat

Market Focus08-01 00:14

On August 1, Neurocrine Biosciences fell 9.92% in regular trading, trading at $167.10 per share, with turnover of $376 million.

On the news front, the company reported Q2 results after market close on July 30 that significantly exceeded expectations. Adjusted earnings per share came in at $2.85, representing a 72.73% year-over-year increase and beating the analyst consensus estimate of $1.34 by 112.69%. Revenue reached $959 million, up 39.4% year-over-year, surpassing the consensus estimate of $883 million. The company simultaneously raised its full-year net sales guidance for core product Ingrezza to $2.825 billion to $2.875 billion, up from a prior range of $2.7 billion to $2.8 billion.

Despite the comprehensive earnings beat and raised guidance, the stock experienced substantial selling pressure. Morgan Stanley had previously identified Ingrezza as the company's core value driver supporting long-term growth, noting durable demand with double-digit volume growth. Deutsche Bank raised its price target to $190 from $170 following the results.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1127772732?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-01 00:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1127772732","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Neurocrine Biosciences Falls 9.92% in Regular Trading, Stock Under Pressure Despite Massive Q2 Earnings Beat","media":"Market Focus","content":"<p><p>On August 1, Neurocrine Biosciences fell 9.92% in regular trading, trading at $167.10 per share, with turnover of $376 million.</p><p>On the news front, the company reported Q2 results after market close on July 30 that significantly exceeded expectations. Adjusted earnings per share came in at $2.85, representing a 72.73% year-over-year increase and beating the analyst consensus estimate of $1.34 by 112.69%. Revenue reached $959 million, up 39.4% year-over-year, surpassing the consensus estimate of $883 million. The company simultaneously raised its full-year net sales guidance for core product Ingrezza to $2.825 billion to $2.875 billion, up from a prior range of $2.7 billion to $2.8 billion.</p><p>Despite the comprehensive earnings beat and raised guidance, the stock experienced substantial selling pressure. Morgan Stanley had previously identified Ingrezza as the company's core value driver supporting long-term growth, noting durable demand with double-digit volume growth. Deutsche Bank raised its price target to $190 from $170 following the results.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Neurocrine Biosciences Falls 9.92% in Regular Trading, Stock Under Pressure Despite Massive Q2 Earnings Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Neurocrine Biosciences Falls 9.92% in Regular Trading, Stock Under Pressure Despite Massive Q2 Earnings Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-01 00:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 1, Neurocrine Biosciences fell 9.92% in regular trading, trading at $167.10 per share, with turnover of $376 million.</p><p>On the news front, the company reported Q2 results after market close on July 30 that significantly exceeded expectations. Adjusted earnings per share came in at $2.85, representing a 72.73% year-over-year increase and beating the analyst consensus estimate of $1.34 by 112.69%. Revenue reached $959 million, up 39.4% year-over-year, surpassing the consensus estimate of $883 million. The company simultaneously raised its full-year net sales guidance for core product Ingrezza to $2.825 billion to $2.875 billion, up from a prior range of $2.7 billion to $2.8 billion.</p><p>Despite the comprehensive earnings beat and raised guidance, the stock experienced substantial selling pressure. Morgan Stanley had previously identified Ingrezza as the company's core value driver supporting long-term growth, noting durable demand with double-digit volume growth. Deutsche Bank raised its price target to $190 from $170 following the results.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NBIX","symbol_name":"神经分泌生物科学","start_time":0,"source_url":"","article_id":"1127772732","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1127772732","pubTimestamp":1785514475,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 1, Neurocrine Biosciences fell 9.92% in regular trading, trading at $167.10 per share, with turnover of $376 million.On the news front, the company reported Q2 results after market close on...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NBIX":"神经分泌生物科学"},"translate_title":"走势警报|Neurocrine Biosciences 常规交易中下跌 9.92%，尽管第二季度盈利大幅超出预期，但该股仍面临压力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NBIX":1},"content_text":"On August 1, Neurocrine Biosciences fell 9.92% in regular trading, trading at $167.10 per share, with turnover of $376 million.On the news front, the company reported Q2 results after market close on July 30 that significantly exceeded expectations. Adjusted earnings per share came in at $2.85, representing a 72.73% year-over-year increase and beating the analyst consensus estimate of $1.34 by 112.69%. Revenue reached $959 million, up 39.4% year-over-year, surpassing the consensus estimate of $883 million. The company simultaneously raised its full-year net sales guidance for core product Ingrezza to $2.825 billion to $2.875 billion, up from a prior range of $2.7 billion to $2.8 billion.Despite the comprehensive earnings beat and raised guidance, the stock experienced substantial selling pressure. Morgan Stanley had previously identified Ingrezza as the company's core value driver supporting long-term growth, noting durable demand with double-digit volume growth. Deutsche Bank raised its price target to $190 from $170 following the results.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1127772732","isCrawlerRequest":true}